Last reviewed · How we verify
A Double-Blind,Venlafaxine-Controlled Study of Efficacy and Safety of Sustained-Release Desvenlafaxine Hydrochloride in the Treatment of Major Depressive Disorder
A multicenter, 10-week study to evaluate the efficacy and safety of Sustained-Release Desvenlafaxine Hydrochloride versus Sustained-Release venlafaxine Hydrochloride in adult with major depressive disorder.
Details
| Lead sponsor | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
|---|---|
| Phase | Phase 2/Phase 3 |
| Status | UNKNOWN |
| Enrolment | 300 |
| Start date | 2013-10 |
Conditions
- Major Depressive Disorder
Interventions
- Sustained-Release Desvenlafaxine Hydrochloride
- Sustained-Release Venlafaxine Hydrochloride
Primary outcomes
- Change From Baseline on the Hamilton Rating Scale for Depression, 17-item Total Score (HAM-D17) — Baseline to Week 10
Countries
China